New directions of drugs Milgamma and Milgamma compositum use in the diabetes mellitus


Cite item

Full Text

Abstract

Milgamma and Milgamma compositum administration provide a wide range of favorable therapeutic effects: neuropathic pain relief, prevention of retinopathy progression, the elimination of oxidative stress in retina, brain, kidneys tissues, reducing endothelial dysfunction and endothelial apoptosis, lipid metabolism improvement, glucose metabolism normalization in patients with diabetes mellitus. This defines a favorable effect Milgamma and Milgamma compositum on the development of macro- and microvascular complications of diabetes. In addition to diabetes, these drugs administration favorably influence on course of uremia, including patients on dialysis, and may be useful in a number of other states, accompanied by thiamine deficiency.

About the authors

V V Den'gin

V V Dengin

References

  1. Бадалян О.Л., Крикова Е.В., Тертышник О.Ю. и др. Применение Мильгаммы и Мильгаммы композитум в лечении полиневропатий различного генеза // Фарматека. 2009. № 7. С. 63-68.
  2. Berrone E, Beltramo E, Solimine C, et al. Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose. J Biol Chem 2006;281(14):9307-13.
  3. Hammes HP, Du X, Edelstein D, Taguchi T, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003;9(3):294-99.
  4. Yadav UC, Subramanyam S, Ramana KV. Prevention of endotoxin-induced uveitis in rats by benfotiamine, a lipophilic analogue of vitamin B1. Invest Ophthalmol Vis Sci 2009;50(5):2276-82.
  5. Giusti C, Gargiulo P. Advances in biochemical mechanisms of diabetic retinopathy. Eur Rev Med Pharmacol Sci 2007;11(3):155-63.
  6. Schmid U, Stopper H, Heidland A, et al. Benfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage in vitro. Diabetes Metab Res Rev 2008;24(5):371-77.
  7. Wu S, Ren J. Benfotiamine alleviates diabetes-induced cerebral oxidative damage independent of advanced glycation end-product, tissue factor and TNF-alpha. Neurosci Lett 2006;394(2):158-62.
  8. Frank T, Bitsch R, Maiwald J, et al. Alteration of thiamine pharmacokinetics by end-stage renal disease (ESRD). Int J Clin Pharmacol Ther 1999;37(9):449-55.
  9. Frank T, Bitsch R, Maiwald J, et al. High thiamine diphosphate concentrations in erythrocytes can be achieved in dialysis patients by oral administration of benfontiamine. Eur J Clin Pharmacol 2000;56(3):251-57.
  10. Schupp N, Dette EM, Schmid U, et al. Benfotiamine reduces genomic damage in peripheral lymphocytes of hemodialysis patients. Naunyn Schmiedebergs Arch Pharmacol 2008;378(3):283-91.
  11. Balakumar P, Sharma R, Singh M. Benfotiamine attenuates nicotine and uric acid-induced vascular endothelial dysfunction in the rat. Pharmacol Res 2008;58(5-6):356-63.
  12. Babaei-Jadid R, Karachalias N, Ahmedm N, et al. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 2003;52:2110-20.
  13. Marchetti V, Menghini R, Rizza S, et al. Benfotiamine counteracts glucose toxicity effects on endothelial progenitor cell differentiation via Akt/FoxO signaling. Diabetes 2006;55(8):2231-37.
  14. Gadau S, Emanueli C, Van Linthout S, et al. Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis. Diabetologia 2006;49(2):405-20.
  15. Gotting Ch, Kleesiek K, Negrean M, et al. Adiponectin decreases postprandially following a heat-processed meal in individuals with type 2 diabetes: an effect prevented by benfotiamine and cooking method. Diabetes Care 2007;30(10):2514-16.
  16. Stirban A, Negrean M, Statmann B, et al. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 2006;29:2064-71.
  17. Du X, Edelstein D, Brownlee M. Oral benfotiamine plus alpha-lipoic acid normalises complication-causing pathways in type 1 diabetes. Diabetologia 2008;51(10):1930-32.
  18. Karachalias N, Babaei-Jadidi R, Kupich C, et al. High-dose thiamine therapy counters dyslipidemia and advanced glycation of plasma protein in streptozotocin-induced diabetic rats. Ann N Y Acad Sci 2005;1043:777-83.
  19. Ceylan-Isik AF, Wu S, Li Q, et al. High-dose benfotiamine rescues cardiomyocyte contractile dysfunction in streptozotocin-induced diabetes mellitus. J Appl Physiol 2006;100(1):150-56.
  20. Коломойская М.В., Дегонский А.И., Гришина Р.А. Сократительная функция миокарда и центральная гемодинамика у больных инсулинзависимым сахарным диабетом в процессе лечения // Проблемы эндокринологии. 1989. №35(4). С. 12-15.
  21. Удовиченко О.В., Курцева Т.Г. Эффективность препарата Мильгамма в лечении болевого синдрома и трофических язв при диабетической полиневропатии // Клиническая диабетология. 1999. № 2. С. 32-34.
  22. Haupt E, Ledermann H, Kopcke W. Benfotiamine in the treatment of diabetic polyneuropathy - a three-week randomized, controlled pilot study (BEDIP study). Int J Clin Pharmacol Ther 2005;43:71-77.
  23. Stracke H, Gaus W, Achenbach U, et al. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes 2008;116(10):600-05.
  24. Строков И.А., Ахмеджанова Л.Т., Солоха О.А. и др. Лечение алкогольной и диабетической полиневропатий витаминами группы В // Фарматека. 2009. № 8. С. 33-38.
  25. Mixcoatl-Zecuatl T, Quinonez-Bastidas GN, Caram-Salas NL, et al. Synergistic antiallodynic interaction between gabapentin or carbamazepine and either benfotiamine or cyanocobalamin in neuropathic rats. Methods Find Exp Clin Pharmacol 2008;30(6):431-41.
  26. Várkonyi T, Kempler P. Diabetic neuropathy: new strategies for treatment. Diabetes Obes Metab 200810(2):99-108.
  27. Bitsch R, Wolf M, Moller J, et al. Bioavailability assessment of the lipophilic benfotiamine as compared to a water-soluble thiamin derivative. Ann Nutr Metab 1991;35(5):292-96.
  28. Simeonov S, Pavlova M, Mitkov M, et al. Therapeutic efficacy of "Milgamma" in patients with painful diabetic neuropathy. Folia Med (Plovdiv) 1997;39(4):5-10.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies